Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-001 oral LOXO-292 in advanced RET-altered solid tumors
NL-OMON48590Phase 2Withdrawn
- Sponsor
- Loxo Oncology
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selpercatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and 3 more, sponsored by Loxo Oncology. Primary endpoint: Maximum tolerated dose or recommended dose for further study. Planned start Sep 2018; status: withdrawn.
02
Drugs
selpercatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)papillary thyroid cancer (PTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON48590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48590.